# To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

> **NCT06504732** · PHASE2,PHASE3 · RECRUITING · sponsor: **SUNHO（China）BioPharmaceutical CO., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Stomach Neoplasms
- Solid Tumor

## Interventions

- **DRUG:** IAH0968

## Key facts

- **NCT ID:** NCT06504732
- **Lead sponsor:** SUNHO（China）BioPharmaceutical CO., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2026-07
- **Final completion:** 2028-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504732, "To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06504732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*